Last updated: October 27, 2026
Neulasta Onpro is Amgen’s on-body delivery presentation of pegfilgrastim, a long-acting granulocyte colony-stimulating factor used to reduce the incidence of infection associated with febrile neutropenia in patients receiving myelosuppressive chemotherapy. Its commercial value has declined sharply as pegfilgrastim biosimilars entered the U.S. market, but the Onpro delivery system continues to differentiate the product from conventional prefilled syringes.
Amgen does not disclose separate revenue for Neulasta Onpro. Sales are reported within the broader Neulasta franchise, which fell from more than $4 billion annually at its peak to approximately $1.9 billion in 2023. The key commercial risks are biosimilar substitution, payer formulary pressure, reduced oncology utilization, and the availability of competing on-body devices.
What is Neulasta Onpro and how does it compete?
Neulasta Onpro combines pegfilgrastim with an on-body injector that is applied to the patient after chemotherapy. The device automatically delivers the dose approximately 27 hours later, eliminating the need for a separate clinic visit for administration.
The product competes on convenience rather than molecule-level differentiation. Pegfilgrastim biosimilars generally provide the same active biological mechanism but have historically been marketed in prefilled syringes. That distinction gave Neulasta Onpro a degree of protection in community oncology practices where avoiding return visits has operational and economic value.
| Attribute |
Neulasta Onpro |
| Active ingredient |
Pegfilgrastim |
| Sponsor |
Amgen |
| Reference product |
Neulasta |
| FDA approval |
Neulasta, 2002; Onpro presentation, 2015 |
| Administration |
Subcutaneous on-body injector |
| Standard timing |
Approximately 27 hours after chemotherapy |
| Primary use |
Prevention of chemotherapy-induced febrile neutropenia |
| Regulatory pathway |
Biologic license application |
| Main competitors |
Fulphila, Udenyca, Ziextenzo, Nyvepria, Stimufend, Fylnetra and other pegfilgrastim products |
| Separate Onpro revenue disclosure |
None |
The Onpro device is not a different active ingredient. It is a delivery presentation of the same pegfilgrastim product.
How has Neulasta revenue changed?
Neulasta revenue has followed the standard trajectory of a mature biologic exposed to biosimilar competition: rapid erosion after biosimilar entry, followed by continued but declining residual sales supported by brand loyalty, delivery-system differentiation and contracting.
Amgen reports Neulasta sales at the franchise level and does not separate Onpro from the prefilled syringe presentation.
| Fiscal year |
Approximate Neulasta sales |
Year-over-year direction |
| 2018 |
$4.3 billion |
High point before U.S. biosimilar erosion |
| 2019 |
$3.6 billion |
Decline begins |
| 2020 |
Approximately $3.0 billion |
Continued erosion |
| 2021 |
Approximately $2.7 billion |
Continued decline |
| 2022 |
$2.43 billion |
Down approximately 12% |
| 2023 |
$1.87 billion |
Down approximately 23% |
| 2024 |
Approximately $1.6 billion |
Further decline |
Sources: Amgen annual reports and Form 10-K filings.[1-5]
The decline reflects several overlapping factors:
- U.S. biosimilar entry began in 2018 with pegfilgrastim products such as Fulphila.
- Payers increased use of lower-cost alternatives.
- Providers gained access to multiple competing pegfilgrastim products.
- Biosimilars expanded from prefilled syringes into on-body delivery.
- Amgen’s gross-to-net deductions increased as contracting became more aggressive.
Neulasta remains commercially material, but its contribution to Amgen’s overall business has contracted. Amgen’s total revenue has become increasingly dependent on newer products, including Repatha, Prolia, Xgeva, Otezla and newer acquired or internally developed therapies.
When did Neulasta lose market exclusivity?
Neulasta’s core market exclusivity expired before biosimilar products entered the U.S. market. The reference product benefited from biologic exclusivity and patent protection, but those protections did not prevent subsequent 351(k) biosimilar approvals.
The Biologics Price Competition and Innovation Act provides 12 years of reference-product exclusivity for a licensed biologic. Neulasta was approved in 2002, placing the end of its reference-product exclusivity period in 2014, subject to statutory and regulatory calculations. The first U.S. pegfilgrastim biosimilars were approved in 2018.[6]
Neulasta exclusivity timeline
| Event |
Date |
| Neulasta approved by FDA |
2002 |
| Core biologic exclusivity period |
Expired in the mid-2010s |
| Onpro approved |
2015 |
| First U.S. pegfilgrastim biosimilar approval |
2018 |
| U.S. biosimilar competition |
Ongoing |
| Current reference-product exclusivity |
None |
The Onpro approval did not restart 12 years of biologic exclusivity for the active ingredient. A new delivery presentation can receive separate patent protection, but it does not automatically receive a new reference-product exclusivity period.
What patents protect Neulasta Onpro?
The key patent question is divided between pegfilgrastim patents and device or combination-product patents.
Core pegfilgrastim patents have expired or are no longer an effective barrier to biosimilar competition. The more commercially relevant residual protection has related to the Onpro delivery system, injector configuration, use instructions and device-related combinations.
Because Neulasta is regulated as a biologic, it does not follow the conventional small-molecule Orange Book framework. Biosimilar applicants generally use the 351(k) pathway rather than filing an ANDA with a Paragraph IV certification.
Patent categories
| Patent category |
Commercial relevance |
| Pegfilgrastim composition or conjugate patents |
Core molecule protection; largely expired |
| Dosing and treatment patents |
May cover specific chemotherapy-support methods, but usually has limited ability to block all biosimilar sales |
| On-body injector patents |
Can create device-specific litigation and design-around issues |
| Drug-device combination patents |
May protect delivery of pegfilgrastim through a particular injector |
| Manufacturing patents |
Can increase technical barriers but generally do not prevent use of an alternative manufacturing process |
| Pediatric or regulatory exclusivity |
No current meaningful barrier to biosimilar entry |
The patent estate is therefore best characterized as commercially weakened but not irrelevant. A biosimilar sponsor can enter with a conventional syringe even if it faces device-related patent issues involving an on-body presentation. Conversely, a competing on-body product may need to address device patents separately.
What is the Orange Book status of Neulasta Onpro?
Neulasta Onpro does not have the same Orange Book position as a conventional small-molecule drug.
The FDA Orange Book is primarily used for approved drug products evaluated through the abbreviated new drug application pathway. Neulasta is a biologic licensed under a biologics license application. Its competitive framework is the Purple Book and the 351(k) biosimilar pathway, not an ANDA-based Paragraph IV system.[7]
This distinction has practical consequences:
- There is no conventional ANDA Paragraph IV challenge to Neulasta.
- Biosimilar applicants rely on the BPCIA patent-information exchange and litigation framework.
- Patent disputes may occur before or after FDA approval.
- FDA approval does not resolve all patent issues.
- Reference-product patents and device patents can be litigated separately.
Which companies are challenging Neulasta’s market position?
The principal competitive threat comes from manufacturers of pegfilgrastim biosimilars and competing on-body delivery systems.
| Company |
Product |
Competitive position |
| Biocon Biologics and Viatris |
Fulphila |
Early U.S. pegfilgrastim biosimilar entrant |
| Sandoz |
Ziextenzo |
Pegfilgrastim biosimilar with U.S. commercial presence |
| Coherus BioSciences |
Udenyca |
Major commercial competitor; later expanded into an on-body presentation |
| Pfizer |
Nyvepria |
Biosimilar pegfilgrastim product |
| Fresenius Kabi |
Stimufend |
U.S. pegfilgrastim biosimilar |
| Amneal |
Fylnetra |
Additional biosimilar competitor |
| Other manufacturers |
Multiple pegfilgrastim products |
Increase formulary and contracting pressure |
Udenyca is particularly important because Coherus developed an on-body delivery product intended to compete directly with the convenience proposition of Neulasta Onpro. The competitive distinction between "syringe biosimilar" and "on-body brand" has therefore narrowed.
What is the FDA status of competing pegfilgrastim products?
The FDA has approved multiple pegfilgrastim biosimilars. Approval establishes that the product is highly similar to Neulasta and has no clinically meaningful differences in safety, purity and potency under the approved conditions of use.
Interchangeability is a separate designation from biosimilarity. An interchangeable biosimilar may be substituted at the pharmacy level under applicable state law, although substitution rules vary by jurisdiction and payer arrangement.
The commercial implications are significant:
- Biosimilar approval expands physician and payer choice.
- Interchangeability can strengthen automatic substitution potential.
- On-body delivery may reduce the practical advantage of Neulasta Onpro.
- Payers can use preferred-product status and prior authorization to steer utilization.
- Provider economics can determine whether a lower acquisition cost translates into actual substitution.
How strong is the Neulasta Onpro patent estate?
The estate is moderate for the device presentation and weak for the underlying molecule.
Stronger elements
Onpro’s strongest protection has historically involved:
- Proprietary injector architecture.
- Drug-device integration.
- Timing and activation mechanisms.
- Wearability and automatic delivery.
- Specific methods of administering pegfilgrastim after chemotherapy.
These claims can raise development costs for a direct on-body competitor and may support settlement negotiations.
Weaker elements
The estate is less effective against:
- Conventional pegfilgrastim prefilled syringes.
- Alternative injector designs.
- Different device assembly methods.
- Biosimilar products that avoid the asserted claim scope.
- Products entering after core molecule patents have expired.
The commercial moat is therefore based more on accumulated physician familiarity, patient convenience, manufacturing scale and payer contracting than on broad, unexpired composition-of-matter protection.
What patent litigation and settlements affect Neulasta?
Pegfilgrastim competition has produced patent disputes involving Amgen and biosimilar manufacturers. The litigation has generally focused on BPCIA information exchange, patent infringement claims, launch timing and settlement terms.
Several biosimilar entrants reached commercial arrangements or settlements that permitted U.S. launch before the expiration of every potentially relevant patent claim. Settlement terms are usually confidential, making it difficult to quantify the value transferred or the precise launch constraints from public filings alone.
The main legal pattern has been:
- Biosimilar sponsor files or prepares a 351(k) application.
- Amgen receives notice of commercial marketing or initiates BPCIA procedures.
- The parties litigate composition, formulation, manufacturing or device-related claims.
- The dispute resolves through litigation, settlement, license, or a combination.
- The biosimilar launches under agreed timing and commercial terms.
There is no current indication that the original Neulasta patent estate can restore exclusivity for the molecule. Litigation risk is more relevant to the timing and format of specific competitor launches than to the survival of the franchise as a whole.
What formulations and delivery systems are protected?
Neulasta Onpro is protected commercially by the combination of pegfilgrastim and a wearable injector. The delivery system has several advantages over a clinic-administered injection:
- It reduces a post-chemotherapy return visit.
- It allows dosing at the intended post-treatment interval.
- It can improve practice workflow.
- It creates a branded device experience that is difficult to replicate exactly.
Those advantages are narrowing. Competing pegfilgrastim products have increasingly offered alternative administration formats, and the emergence of another on-body product reduces Onpro’s differentiation.
The most important formulation risk is that a biosimilar does not need to duplicate every physical characteristic of Onpro. It can compete through a prefilled syringe, autoinjector or alternative on-body system while relying on the same therapeutic mechanism.
How does Neulasta Onpro compare with pegfilgrastim biosimilars?
| Factor |
Neulasta Onpro |
Pegfilgrastim biosimilars |
| Active ingredient |
Pegfilgrastim |
Pegfilgrastim |
| Clinical role |
Prevention of febrile neutropenia |
Same |
| Delivery |
On-body injector or syringe |
Mostly syringes, with on-body alternatives emerging |
| Brand history |
Long-established |
Shorter commercial history |
| Price |
Generally higher before rebates |
Lower list and net pricing potential |
| Payer leverage |
Declining |
Increasing |
| Switching barrier |
Device familiarity and workflow |
Acquisition cost and formulary placement |
| Patent position |
Device-related residual protection |
Design-around and litigation exposure |
| Substitution |
Depends on product designation and state law |
Stronger for interchangeable products |
For health systems, the decision is not based only on unit acquisition price. The relevant economic comparison includes:
- Administration labor.
- Avoided clinic visits.
- Patient transportation.
- Device failure or replacement risk.
- Product acquisition cost.
- Reimbursement methodology.
- Payer-specific authorization rules.
Onpro can remain economically viable where avoiding an additional clinic visit offsets its premium. That advantage is weaker in systems with high biosimilar discounts, strong payer steering or established infusion-center infrastructure.
What is the generic launch risk for Neulasta Onpro?
The relevant launch risk is biosimilar, not generic.
Base-case scenario
Neulasta sales continue to decline as payers expand biosimilar coverage and additional delivery systems reach the market. Onpro retains a meaningful share of branded pegfilgrastim use but becomes concentrated in accounts that value convenience or have favorable Amgen contracting.
Upside scenario for Amgen
Amgen slows erosion if it:
- Maintains preferred payer placement.
- Offers competitive rebates.
- Retains major oncology-group accounts.
- Demonstrates lower total treatment cost through Onpro.
- Protects device differentiation through patents and reliability.
- Uses the Onpro platform to preserve switching resistance.
Downside scenario for Amgen
Revenue erosion accelerates if:
- A competing on-body product receives broad formulary placement.
- Payers make biosimilar substitution routine.
- Interchangeable products gain pharmacy-level substitution.
- Providers accept lower-cost syringes despite added administration requirements.
- Onpro device patents expire without effective commercial replacement.
- Amgen reduces investment in the mature franchise.
How does geographic coverage affect the franchise?
The United States remains the most important profit pool for Neulasta and Neulasta Onpro. U.S. commercial dynamics are shaped by biosimilar adoption, Medicare policy, private payer contracting and provider economics.
Outside the United States, pegfilgrastim faces different pricing, reimbursement and substitution rules. Biosimilar penetration can be faster where centralized health systems conduct tendering or mandate lower-cost products. The Onpro presentation is also less valuable in markets where patients already receive centralized outpatient care or where home administration is less operationally important.
Geographic expansion cannot offset the U.S. erosion of a mature product at its historical scale. The key value driver is retention of high-margin U.S. utilization.
What manufacturing and intellectual-property barriers remain?
Pegfilgrastim manufacturing requires control of:
- Recombinant protein production.
- Site-specific or controlled PEG conjugation.
- Purification and characterization.
- Aggregation and impurity control.
- Sterility and container-closure performance.
- Stability during storage and transport.
- Device assembly and drug-device compatibility.
These requirements create technical barriers, but they are not equivalent to market exclusivity. Experienced biosimilar manufacturers can address them through process development, analytical comparability and regulatory experience.
The Onpro device adds another manufacturing layer. Competitors must establish injector reliability, patient adherence, activation timing, dose delivery and safe disposal. Device complexity can slow launch and increase quality-system requirements, but it does not prevent competition indefinitely.
What is the financial outlook for Neulasta Onpro?
Neulasta Onpro is a declining but still cash-generative franchise. Its future value depends on the rate of biosimilar conversion rather than on market expansion.
The financial trajectory can be summarized as follows:
- Peak sales exceeded $4 billion before U.S. biosimilar entry.
- Revenue declined materially after 2018.
- Sales fell below $2 billion by 2023.
- The franchise is likely to continue declining as on-body competition develops.
- Residual profitability should remain attractive because the product is mature and manufacturing infrastructure is established.
- The franchise is unlikely to return to historical growth without a major change in reimbursement, exclusivity or delivery technology.
Neulasta’s financial exposure is meaningful for Amgen but no longer central to the company’s growth profile. Investors should treat it as a mature-product cash-flow asset with declining volume and increasing contracting pressure, not as a growth driver.
Key Takeaways
- Neulasta Onpro is Amgen’s pegfilgrastim on-body injector presentation.
- Amgen does not disclose separate Onpro revenue.
- Neulasta franchise revenue declined from roughly $4.3 billion in 2018 to about $1.9 billion in 2023.
- The core biologic exclusivity period has expired, and multiple pegfilgrastim biosimilars compete in the United States.
- The relevant regulatory framework is the BPCIA and 351(k) biosimilar pathway, not a conventional ANDA Paragraph IV challenge.
- Neulasta Onpro’s strongest remaining differentiation is its delivery system, not the pegfilgrastim molecule.
- Udenyca and other competing products weaken the historical advantage of an on-body presentation.
- Patent disputes may affect individual launch timing, but they are unlikely to restore broad Neulasta exclusivity.
- The franchise remains profitable but faces continuing revenue erosion from biosimilar substitution and payer contracting.
FAQs
Is Neulasta Onpro interchangeable with pegfilgrastim biosimilars?
No. Interchangeability depends on the FDA designation of the specific biosimilar and applicable state substitution law. Biosimilarity alone does not automatically authorize pharmacy-level substitution.
Does Neulasta Onpro have a new patent term separate from Neulasta?
The Onpro device and drug-device combination may have separate patent claims, but approval of the delivery presentation does not create a new 12-year biologic exclusivity period for pegfilgrastim.
Can a biosimilar manufacturer copy the Neulasta Onpro device?
A competitor can develop an alternative on-body injector, but it must avoid valid, enforceable device and combination-product claims. It does not need to duplicate every physical feature of the Onpro system.
Why do some oncology practices continue using Neulasta Onpro?
Practices may value reduced return visits, established workflow, patient familiarity, reimbursement economics and payer coverage. Those factors can outweigh the lower acquisition price of a biosimilar in selected accounts.
Is Neulasta Onpro still a major Amgen product?
It remains a material revenue contributor but is no longer a growth product. Its sales and strategic importance have declined as biosimilars captured pegfilgrastim volume.
References
- Amgen Inc. (2019). 2018 annual report.
- Amgen Inc. (2020). 2019 annual report.
- Amgen Inc. (2021). 2020 annual report.
- Amgen Inc. (2023). 2022 annual report.
- Amgen Inc. (2024). 2023 annual report.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations and biologics regulatory resources.
